Tempus AI (TEM) Stock: Plunge as FDA Clears xT CDx Tumor-Only Cancer Test

TLDR

• Tempus AI stock drops 1.66% despite FDA approval for xT CDx test
• TEM rally fades after FDA clears tumor-only cancer profiling test
• Tempus secures FDA nod for expanded xT CDx cancer test use
• TEM slips as FDA approval adds new cancer testing pathway
• Tempus AI gains FDA clearance, but stock reverses early spike

Tempus AI (TEM) shares slipped despite a key FDA approval for its xT CDx cancer test. TEM traded at $50.44, down $0.85, or 1.66%. The stock earlier touched nearly $55 before late-morning selling erased the gain.

Tempus AI, Inc., TEM

TEM Stock Falls After Early Rally Fades

Tempus AI opened with stronger momentum after the company announced a new FDA approval. However, the move lost strength as trading progressed. TEM then dropped into negative territory by late morning.

The stock’s fall showed a sharp reversal from its early high near $55. The move placed TEM below its earlier session strength. It also kept the share price under pressure despite the regulatory update.

Tempus AI trades on Nasdaq under the ticker TEM. The company focuses on artificial intelligence tools for precision medicine. Its latest FDA approval adds another regulated product pathway to its cancer testing business.

FDA Clears Tumor-Only xT CDx Cancer Test

The FDA approved a tumor-only indication for Tempus xT CDx. The platform uses next-generation sequencing for genomic profiling in solid tumor cancers. The approval expands the test beyond its earlier tumor-normal sample requirement.

Tempus said the approval makes it the first laboratory with FDA CDx approval for both formats. These formats include tumor-only and tumor-normal comprehensive genomic profiling. The decision gives clinicians more flexibility when matched normal samples are unavailable.

The xT CDx test analyzes 648 genes from tumor tissue samples. It detects substitutions, insertions, deletions, and microsatellite instability status. It also supports molecular profiling for patients with previously diagnosed solid malignant tumors.

Approval Adds Reimbursement and Treatment Context

Tempus linked the approval to its wider reimbursement strategy. The company said it can move its DNA solid tumor portfolio toward FDA-approved assays. It also said the products can fall under its current ADLT pricing framework.

Chief Financial Officer Jim Rogers said the approval supports unified ADLT pricing for the solid tumor DNA portfolio. He also said Tempus expects an estimated $200 average selling price benefit from 2027. The company tied that expected benefit directly to the new approval.

Tempus xT CDx also serves as a companion diagnostic for colorectal cancer treatment selection. The test can identify patients who may benefit from Erbitux and Vectibix. Therefore, the approval adds clinical reach while TEM shares still posted a session decline.

The post Tempus AI (TEM) Stock: Plunge as FDA Clears xT CDx Tumor-Only Cancer Test appeared first on CoinCentral.